Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

A marker linked to inflammation, C-reactive protein, may increase significantly during the follicular phase of the menstrual ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Sickle cell disease is the most common inherited haemoglobinopathy in Tanzania, with 11 000– 14 000 children born with the ...